National Guideline on Drug Resistant TB Management 2019, Nepal
Risk Population for DR-TB (Ref. Page no. 11)
The following categories of TB patients are at risk of having DR-TB and need to be screened for drug resistance;
- Close contact of DR-TB case
- Previously treated patients who either:
– returned after loss to follow-up
- Smear positive at 2 months or subsequent follow up during first-line treatment
- Not getting better / getting worse during continuation phase of the first-line treatment and patients with frequent interruptions and irregular first line drugs.
- Health care workers with presumptive TB.
- PLHIV, DM and other immunocompromised
- Belonging to vulnerable groups such as migrants and refugees
Most patients with presumptive DR-TB will be bacteriologically positive pulmonary cases, but clinically confirmed pulmonary or extrapulmonary TB cases may also present with presumptive DR-TB if they show a clinically unfavorable evolution.
Prevention of drug-resistant TB (Ref. Page no. 6)
- Early detection and high-quality treatment of drug-susceptible TB.
- Early detection and high-quality treatment of drug-resistant TB.
- Effective implementation of infection control measures.
- Strengthening and regulation of health systems.
- Addressing underlying risk factors and social determinants
- Global Tuberculosis Report 2019: Latest status of the tuberculosis epidemic
- Dissemination of Findings and Recommendations of Joint External Monitoring Mission(JEMM) of Nepal National Tuberculosis Program
- National Tuberculosis Programme Annual Report 2018
- National Strategic Plan for Tuberculosis Prevention, Care and Control 2016 – 2021
- NTP, Nepal: New TB Treatment Algorithm & Regimen (Updated)
- WHO announces landmark changes in MDR-TB treatment regimens
- TB Vaccine results announce a promising step towards ending the emergency
- 7 million people receive record levels of lifesaving TB treatment but 3 million still miss out